Skip to main content

Table 1 Baseline demographic and clinical features of RA, OA and Orth.A patients in the study of synovial PGC-1β by immunohistochemistry

From: Down-regulating peroxisome proliferator-activated receptor-gamma coactivator-1beta alleviates the proinflammatory effect of rheumatoid arthritis fibroblast-like synoviocytes through inhibiting extracellular signal-regulated kinase, p38 and nuclear factor-kappaB activation

Characteristic RA patients (n = 31) OA patients (n = 13) Orth.A patients (n = 10)
Demographic    
Age, yrs, median (IQR) 61 (53 to 66) 61 (56 to 65) 32 (25 ~ 44)
Female, n (%) 24 (77.4) 11 (84.6) 5 (50.0)
Disease status    
Disease duration, mo, median (IQR) 36 (12 to 120) 60 (24 to 114) 3 (1 to 39)
ESR, mm/h, median (IQR) 82 (50 to 108) 18 (11 to 33) 14 (5 to 38)
CRP, mg/dl, median (IQR) 4.28 (1.89 to 6.05) 0.33 (0.25 to 0.93) 0.19 (0.08 to 0.34)
Rheumatoid factor-positive, n (%) 28 (90.3) NA NA
Anti-CCP-positive, n (%) 26 (83.9) NA NA
DAS28, median (IQR) 5.78 (4.83 to 6.39) NA NA
Previous medications, n (%)   NA NA
Corticosteroids 12 (38.7) NA NA
Methotrexate 12 (38.7) NA NA
Leflunomide 5 (16.1) NA NA
Sulfasalazine 1 (3.2) NA NA
Hydroxychloroquine 3 (9.7) NA NA
Etanercept 3 (9.7) NA NA
  1. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score 28-joint assessment; n, number of patients; RA, rheumatoid arthritis; OA, osteoarthritis; Orth.A, orthopedic arthropathies; NA, not applicable.